Latin American consensus on the quality indicators for comprehensive care clinics for patients with inflammatory bowel disease: PANCCO-GETECCU J.K. Yamamoto-Furusho; D. Andrade; J. Barahona; S. Bautista; F. Bosques-Padilla; J. de Paula; M.T. Galiano; B. Iade; F. Juliao-Baños; G. Otoya; F. Steinwurz; E. Torres; G. Veitia; M. Barreiro-de Acosta;

Prevalence of extraintestinal manifestations and other associated conditions in a cohort of patients with inflammatory bowel disease at an advanced specialty center in Bogotá, Colombia J. Andrade-Restrepo; D. Rubio-Cruz; J.G. Maigual-Quintas; S.G. Sicard-Gómez; E.J. Cuello-Navarro; L.C. Álvarez-Larrota; R. García-Duperly; E.E. Londoño-Schimmer; A.M. Rey-Rubiano; B. Mendoza de Molano; R.P. López-Panqueva;

ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease A. Jena; N. Grover; P. Bhatia; M. Singh; D. Lad; K.K. Prasad; H. Singh; U. Dutta; V. Sharma;